TESARO Announces First-Quarter 2015 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO (TSRO) Misses Q1 EPS by 18c, Completes Enrollment in Phase 3 NOVA Trial
April 30, 2015 4:58 PM EDTTESARO (NASDAQ: TSRO) reported Q1 EPS of ($1.30), $0.18 worse than the analyst estimate of ($1.12).
TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today provided an update on its niraparib clinical development program. The targeted enrollment has... More
